Scutellarin Improves Type 2 Diabetic Cardiomyopathy by Regulating Cardiomyocyte Autophagy and Apoptosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

1. Global research trends of cell death in diabetic cardiomyopathy from 2000 to 2024: a bibliometric analysis and integrative overview.Journal of cardiothoracic surgery · 2026
   Review
2. [Scutellarin improves metabolic dysfunction-associated steatotic liver disease in rats by regulating MMP7 and LCN2].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
   Article
3. A comprehensive review on diabetic cardiomyopathy (DCM): histological spectrum, diagnosis, pathogenesis, and management with conventional treatments and natural compounds.Naunyn-Schmiedeberg's archives of pharmacology · 2025
   Review
4. Transcriptome Analysis Revealed the Therapeutic Effect of Scutellarin on MASLD.ACS omega · 2025
   Article
5. Chinese medicine targets cellular autophagy against cardiovascular diseases: research progress and future prospects.Frontiers in cardiovascular medicine · 2025
   Review
6. The Protective Effect of Flavonoids in the Diet on Autophagy-Related Cardiac Impairment.Nutrients · 2024
   Review
7. Vasorelaxant effects of biochemical constituents of various medicinal plants and their benefits in diabetes.World journal of diabetes · 2024
   Review
8. A Review on the Natural Products in Treatment of Diabetic Cardiomyopathy (DCM).Reviews in cardiovascular medicine · 2024
   Review
9. Current advances on the therapeutic potential of scutellarin: an updated review.Natural products and bioprospecting · 2024
   Review
10. Targeting autophagy with natural products as a potential therapeutic approach for diabetic microangiopathy.Frontiers in pharmacology · 2024
    Review
11. Scutellarin: pharmacological effects and therapeutic mechanisms in chronic diseases.Frontiers in pharmacology · 2024
    Review
12. Traditional Chinese medicine and its active substances reduce vascular injury in diabetes via regulating autophagic activity.Frontiers in pharmacology · 2024
    Review
13. Recent advances of traditional Chinese medicine against cardiovascular disease: overview and potential mechanisms.Frontiers in endocrinology · 2024
    Review
14. Effects of scutellarin on the mechanism of cardiovascular diseases: a review.Frontiers in pharmacology · 2023
    Review
15. Flavonoids improve type 2 diabetes mellitus and its complications: a review.Frontiers in nutrition · 2023
    Review
16. The Protective Effect of Sheng Mai Yin on Diabetic Cardiomyopathy via NLRP3/Caspase-1 Pathway.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors at 2 institutions in 1 country.

Funding

Abstract

Indexed as